CIDP: Clinical Trials

3 trials for CIDP, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 withdrawn. 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Recruiting 1, Withdrawn 1
Phase 31Withdrawn 1

Follow CIDP: new trials by email Literature Review of CIDP trials Research Report on CIDP

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Phase 2 / Phase 3Withdrawnargenx2026-09-012026-11-13
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunoadsorption, Immunoglobulins - CIDP
Phase 2RecruitingUniversity of Ulm202023-05-012026-05-01
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
lipoic acid - CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
Phase 2CompletedOregon Health and Science University72009-02-012020-08-19

Narrower conditions

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3)

Broader conditions

Autoimmune Diseases (3)  ·  Autoimmune Diseases of the Nervous System (3)  ·  Chronic Disease (3)  ·  Demyelinating Diseases (3)  ·  Disease Attributes (3)  ·  Immune System Diseases (3)  ·  Nervous System Diseases (3)  ·  Neuromuscular Diseases (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Peripheral Nervous System Diseases (3)  ·  Polyneuropathies (3)  ·  Polyradiculoneuropathy (3)

Interventions

Immunoglobulins (1)  ·  Plasmapheresis (1)  ·  Thioctic Acid (1)

Sponsors

Oregon Health and Science University (1)  ·  University of Ulm (1)  ·  argenx (1)

Countries

Germany (1)  ·  United States (1)

Top investigators

Jau-Shin Lou, MD, PhD (1)  ·  Johannes Dorst, Prof (1)